Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (741-750 of 755) with videos related to

Pageof 76
Sort By:
Seminars in Arthritis and Rheumatism|June 27, 2026
Development of a single‑item patient‑reported measure of treatment side‑effect burden in clinical trials of rheumatic and musculoskeletal diseases using stakeholder input and large language model refinementDorthe B Berthelsen, Ben Horgan, Lee Simon, et al.
Annals of the Rheumatic Diseases|December 13, 2016
Update of EULAR recommendations for the treatment of systemic sclerosisOtylia Kowal-Bielecka, Jaap Fransen, Jerome Avouac, et al.
Arthritis Care & Research|November 5, 2011
Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exerciseJaap Fransen, Sindhu R Johnson, Frank van den Hoogen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 26, 2019
Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled TrialDinesh Khanna, Cathie Spino, Sindhu Johnson, et al.
Arthritis Research & Therapy|January 22, 2016
Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patientsMinghua Wu, Shervin Assassi, Gloria A Salazar, et al.
Scandinavian Journal of Rheumatology|October 10, 2017
There is a need for new systemic sclerosis subset criteria. A content analytic approachS R Johnson, M L Soowamber, J Fransen, et al.
Rheumatology (Oxford, England)|June 6, 2018
The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohortsDane H Dougherty, Linda Kwakkenbos, Marie-Eve Carrier, et al.
Clinical and Experimental Rheumatology|January 17, 2012
New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN)Brett D Thombs, Lisa R Jewett, Shervin Assassi, et al.
The Lancet. Respiratory Medicine|July 30, 2016
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trialDonald P Tashkin, Michael D Roth, Philip J Clements, et al.
The New England Journal of Medicine|January 4, 2018
Myeloablative Autologous Stem-Cell Transplantation for Severe SclerodermaKeith M Sullivan, Ellen A Goldmuntz, Lynette Keyes-Elstein, et al.
Pageof 76

Showing results (741-750 of 755) with videos related to

Sort By:
Pageof 76
Seminars in Arthritis and Rheumatism|June 27, 2026
Development of a single‑item patient‑reported measure of treatment side‑effect burden in clinical trials of rheumatic and musculoskeletal diseases using stakeholder input and large language model refinementDorthe B Berthelsen, Ben Horgan, Lee Simon, et al.
Annals of the Rheumatic Diseases|December 13, 2016
Update of EULAR recommendations for the treatment of systemic sclerosisOtylia Kowal-Bielecka, Jaap Fransen, Jerome Avouac, et al.
Arthritis Care & Research|November 5, 2011
Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exerciseJaap Fransen, Sindhu R Johnson, Frank van den Hoogen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 26, 2019
Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled TrialDinesh Khanna, Cathie Spino, Sindhu Johnson, et al.
Arthritis Research & Therapy|January 22, 2016
Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patientsMinghua Wu, Shervin Assassi, Gloria A Salazar, et al.
Scandinavian Journal of Rheumatology|October 10, 2017
There is a need for new systemic sclerosis subset criteria. A content analytic approachS R Johnson, M L Soowamber, J Fransen, et al.
Rheumatology (Oxford, England)|June 6, 2018
The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohortsDane H Dougherty, Linda Kwakkenbos, Marie-Eve Carrier, et al.
Clinical and Experimental Rheumatology|January 17, 2012
New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN)Brett D Thombs, Lisa R Jewett, Shervin Assassi, et al.
The Lancet. Respiratory Medicine|July 30, 2016
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trialDonald P Tashkin, Michael D Roth, Philip J Clements, et al.
The New England Journal of Medicine|January 4, 2018
Myeloablative Autologous Stem-Cell Transplantation for Severe SclerodermaKeith M Sullivan, Ellen A Goldmuntz, Lynette Keyes-Elstein, et al.
Pageof 76